文献速递外周动脉疾病

药物涂层器械治疗慢性肢体威胁性缺血的发展演变

"Evolution of Drug-Coated Devices for the Treatment of Chronic Limb Threatening Ischemia".
PubMed 文献 · Ann Vasc Surg · 2024-04-04

本文以历史叙事方式回顾药物涂层器械在外周动脉疾病中的发展与主要试验,讨论紫杉醇类器械治疗慢性肢体威胁性缺血(CLTI)的疗效。证据提示紫杉醇类治疗不增加死亡风险,股腘动脉病变中紫杉醇球囊与支架的通畅率和免于再干预优于非药物涂层器械,膝下干预未见有临床意义的获益。

要点

  • 紫杉醇类器械治疗外周动脉疾病不增加死亡风险
  • 股腘动脉病变中紫杉醇球囊与支架通畅率和免于再干预优于非药物涂层器械
  • 膝下干预中紫杉醇类治疗未显示较非药物涂层治疗有临床意义的结局

核心结论

  • 证据认为紫杉醇类治疗外周动脉疾病不增加死亡风险。
  • 在CLTI患者中,紫杉醇球囊和支架治疗股腘动脉病变时,通畅率和免于再干预优于非药物涂层器械。
  • 膝下(BTK)干预中,紫杉醇类治疗未显示较非药物涂层治疗有临床意义的结局。
  • 新一代抗增殖药物(西罗莫司、依维莫司)和递送系统(可吸收支架)在膝下干预中显示前景,早期数据提示主要截肢或主要不良肢体事件发生率降低。

研究设计与样本

  • 本文为历史叙事性综述,回顾药物涂层器械在外周动脉疾病中的发展与使用,并讨论主要试验。

主要发现

  • 药物涂层器械采用紫杉醇以减少再狭窄,但主要在以间歇性跛行就诊的患者中研究。
  • 近年出现描述药物涂层器械治疗CLTI患者疗效的数据。
  • 同时,药物涂层器械在外周动脉疾病中的使用存在重大争议。
  • 膝下干预中紫杉醇类治疗未显示较非药物涂层治疗有临床意义的结局。
  • 新一代抗增殖药物(西罗莫司、依维莫司)和递送系统(可吸收支架)的早期数据提示主要截肢或主要不良肢体事件发生率降低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with Chronic Limb Threatening Ischemia (CLTI), endovascular approaches to revascularization are often employed as a component of multimodality care aimed at limb preservation. However, patients with CLTI are also prone to treatment failure, particularly following balloon angioplasty alone. Drug-coated devices utilizing Paclitaxel were developed to decrease restenosis but have been primarily studied in patients presenting with claudication. In recent years, data have emerged which describe the efficacy of drug-coated devices in the treatment of patients with CLTI. Concurrently, there has been major controversy surrounding the use of drug-coated devices in peripheral arterial disease. A historical narrative of the development and use of drug-coated devices for peripheral arterial disease is presented, along with discussion of major trials. Evidence argues that paclitaxel-based therapies for peripheral arterial disease (PAD) do not increase mortality risk compared to nondrug-coated devices. In CLTI patients, paclitaxel-based balloons and stents provide superior patency and freedom reintervention compared to nondrug-coated devices when treating femoropopliteal disease. However, the use of Paclitaxel-based therapies for below-the-knee (BTK) interventions has not been shown to provide clinically meaningful outcomes compared to nondrug-based therapies. Newer generation antiproliferative agents (Sirolimus, Everolimus) and delivery systems (bioabsorbable scaffolds) hold promise for BTK interventions with early data suggesting decreased rates of major amputation or major adverse limb events.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Creeden T, Jones DW. "Evolution of Drug-Coated Devices for the Treatment of Chronic Limb Threatening Ischemia". Ann Vasc Surg. 2024. PMID: 38582201. doi:10.1016/j.avsg.2023.11.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。